Market closed
Coherus BioSciences/$CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus BioSciences
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Ticker
$CHRS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
228
Website
CHRS Metrics
BasicAdvanced
$95M
3.28
$0.25
0.92
-
Price and volume
Market cap
$95M
Beta
0.92
52-week high
$2.61
52-week low
$0.66
Average daily volume
1.9M
Financial strength
Current ratio
1.207
Quick ratio
1.412
Long term debt to equity
-224.114
Total debt to equity
-226.265
Interest coverage (TTM)
-3.47%
Management effectiveness
Return on assets (TTM)
-12.17%
Return on equity (TTM)
-17.52%
Valuation
Price to earnings (TTM)
3.282
Price to revenue (TTM)
0.35
Price to book
-0.71
Price to tangible book (TTM)
-0.51
Price to free cash flow (TTM)
-2.84
Growth
Revenue change (TTM)
3.78%
Earnings per share change (TTM)
-109.85%
3-year revenue growth (CAGR)
-6.50%
3-year earnings per share growth (CAGR)
-59.71%
What the Analysts think about CHRS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Coherus BioSciences stock.
CHRS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CHRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CHRS News
AllArticlesVideos
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire·2 weeks ago
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Coherus BioSciences stock?
Coherus BioSciences (CHRS) has a market cap of $95M as of April 05, 2025.
What is the P/E ratio for Coherus BioSciences stock?
The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 3.28 as of April 05, 2025.
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.